T-cell Non-Hodgkin lymphoma associated with myelodysplasia: A case report in a child

Reis, Gökçe Pınar; Bahadır, Ayşenur; Erduran, Erol

doi:10.17546/msd.421622

Cited by 2 publications

(2 citation statements)

References 24 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stating secondary MDS has long implied the presence of morphological changes induced in bone marrow cells by past treatment. However, later cases of secondary MDS were reported in patients with malignant lymphomas before the onset of treatment, and nonleukemic patients with non-Hodgkin lymphomas display cytomorphological evidence of secondary dyserythropoiesis [ 6 , 63 ].…”

Section: Secondary Mdsmentioning

confidence: 99%

Prognostic Markers of Myelodysplastic Syndromes

et al. 2020

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interplay between genetic and epigenetic factors, including miRNA. In practice, karyotype analysis assigns patients to different prognostic groups, and mutations are often associated with a particular disease phenotype. Among myeloproliferative disorders, secondary MDS is a group of special entities with a typical spectrum of genetic mutations and cytogenetic rearrangements resembling those in de novo MDS. This overview analyzes the present prognostic systems of MDS and the most recent efforts in the search for genetic and epigenetic markers for the diagnosis and prognosis of MDS.

show abstract

Section: Secondary Mdsmentioning

confidence: 99%

Prognostic Markers of Myelodysplastic Syndromes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Secondary MDS is associated with symptomatic PB cytopenias and abnormal BM cell morphology resembling those observed in primary MDS. One important discovery was the fact that patients with non-Hodgkin's lymphomas (NHLs) can develop myelodysplasia even before the onset of treatment [5]. Additionally, one of the common concomitant pathologies in primary and secondary myelodysplasia is anemia.…”

Section: Introductionmentioning

confidence: 99%

The miRNA Profile in Non-Hodgkin’s Lymphoma Patients with Secondary Myelodysplasia

Veryaskina

Титов

Ковынев

et al. 2020

Cells

View full text Add to dashboard Cite

Myelodysplastic syndromes are a group of clonal diseases of hematopoietic stem cells and are characterized by multilineage dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, genetic instability and a risk of transformation to acute myeloid leukemia. Some patients with non-Hodgkin lymphomas (NHLs) may have developed secondary myelodysplasia before therapy. Bone marrow (BM) hematopoiesis is regulated by a spectrum of epigenetic factors, among which microRNAs (miRNAs) are special. The aim of this work is to profile miRNA expression in BM cells in untreated NHL patients with secondary myelodysplasia. A comparative analysis of miRNA expression levels between the NHL and non-cancer blood disorders samples revealed that let-7a-5p was upregulated, and miR-26a-5p, miR-199b-5p, miR-145-5p and miR-150-5p were downregulated in NHL with myelodysplasia (p < 0.05). We for the first time developed a profile of miRNA expression in BM samples in untreated NHL patients with secondary myelodysplasia. It can be assumed that the differential diagnosis for blood cancers and secondary BM conditions based on miRNA expression profiles will improve the accuracy and relevance of the early diagnosis of cancerous and precancerous lesions in BM.

show abstract

T-cell Non-Hodgkin lymphoma associated with myelodysplasia: A case report in a child

Cited by 2 publications

References 24 publications

Prognostic Markers of Myelodysplastic Syndromes

Prognostic Markers of Myelodysplastic Syndromes

The miRNA Profile in Non-Hodgkin’s Lymphoma Patients with Secondary Myelodysplasia

Contact Info

Product

Resources

About